The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively.
Open accessAbstract
Occupancy of specific receptors on neutrophils by adenosine or its analogues diminishes the stimulated release of toxic oxygen metabolites from neutrophils, while paradoxically promoting chemotaxis. We now report evidence that two distinct adenosine receptors are found on neutrophils (presumably the A1 and A2 receptors of other cell types). These adenosine receptors modulate chemotaxis and O2- generation, respectively. N6-Cyclopentyladenosine (CPA), a selective A1 agonist, promoted neutrophil chemotaxis to the chemoattractant FMLP as well as or better than 5'N-ethylcarboxamidoadenosine (NECA). In contrast, CPA did not inhibit O2- generation stimulated by FMLP. Pertussis toxin completely abolished promotion of chemotaxis by CPA but enhanced inhibition by NECA of O2- generation. Disruption of microtubules by colchicine or vinblastine also abrogated the enhancement by NECA of chemotaxis whereas these agents did not markedly interfere with inhibition by NECA of O2- generation. FMLP receptors, once they have bound ligand, shift to a high affinity state and become associated with the cytoskeleton. NECA significantly increased association of [3H]FMLP with cytoskeletal preparations as it inhibited O2-. Disruption of microtubules did not prevent NECA from increasing association of [3H]FMLP with cytoskeletal preparations. Additionally, CPA (A1 agonist) did not increase binding of [3H]FMLP to the cytoskeleton as well as NECA (A2 agonist). These studies indicate that occupancy of one class of adenosine receptors (A1) promotes chemotaxis by a mechanism requiring intact microtubules and G proteins whereas engagement of a second class of receptors (A2) inhibits O2- generation. Signalling via A2 receptors is independent of microtubules, insensitive to pertussis toxin and is associated with binding of [3H]FMLP to cytoskeletal preparations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Nelson, R. D., Quie, P. G., & Simmons, R. L. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.6.1650 · Cited by 1,170
Goldstein, I. M., Roos, D., Kaplan, H. B., & Weissmann, G. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108191 · Cited by 746
Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.
Cronstein, B. N., Kramer, S. B., Weissmann, G., & Hirschhorn, R. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.4.1160 · Cited by 464
Self-citationInhibition of receptor-mediated release of arachidonic acid by pertussis toxin
Bokoch, G. M., & Gilman, A. G. (1984) · Cell · doi:10.1016/0092-8674(84)90008-4 · Cited by 422
Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.
Cronstein, B. N., Levin, R. I., Belanoff, J., Weissmann, G., & Hirschhorn, R. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112638 · Cited by 412
Self-citationOkajima, F., & Ui, M. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89826-x · Cited by 387
Cronstein, B. N., Rosenstein, E. D., Kramer, S. B., Weissmann, G., & Hirschhorn, R. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.1366 · Cited by 345
Self-citationTrussell, L., & Jackson, M. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-10-03306.1987 · Cited by 253
Ohta, H., Okajima, F., & Ui, M. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36325-1 · Cited by 248
Cited by
Receptors for Purines and Pyrimidines
Burnstock, G., & Verkhratsky, A. (2012) · Purinergic Signalling and the Nervous System · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,958
Ischemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,382
Receptors for Purines and Pyrimidines
Ralevic, V., & Burnstock, G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01373-5 · Cited by 2,005
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides
Dubyak, G. R., & el-Moatassim, C. (1993) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1993.265.3.c577 · Cited by 1,237
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Self-citationBours, M. J. L., Swennen, E. L. R., Di Virgilio, F., Cronstein, B. N., & Dagnelie, P. C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.013 · Cited by 1,030
Self-citationThe ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
The Inflammatory Response to Cell Death
Rock, K. L., & Kono, H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151456 · Cited by 912
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 706
Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., & Thiel, M. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104731 · Cited by 696
Fredholm, B. B., Chen, J.-F., Cunha, R. A., Svenningsson, P., & Vaugeois, J.-M. (2005) · International Review of Neurobiology · doi:10.1016/s0074-7742(05)63007-3 · Cited by 692
Cronstein, B. N., Naime, D., & Ostad, E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116884 · Cited by 679
Self-citationThe role of neutrophils in myocardial ischemia–reperfusion injury
Jordan, J. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00187-x · Cited by 646
Purinergic Signaling during Inflammation
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560
Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors
Sitkovsky, M., & Lukashev, D. (2005) · Nature Reviews Immunology · doi:10.1038/nri1685 · Cited by 518
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential
Jacobson, K. A., Van Galen, P. J. M., & Williams, M. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00081a001 · Cited by 456
Self-citationProtective effects of adenosine in myocardial ischemia.
Ely, S. W., & Berne, R. M. (1992) · Circulation · doi:10.1161/01.cir.85.3.893 · Cited by 412
Eltzschig, H. K., Thompson, L. F., Karhausen, J., Cotta, R. J., Ibla, J. C., Robson, S. C., & Colgan, S. P. (2004) · Blood · doi:10.1182/blood-2004-06-2066 · Cited by 370
Drug Antioxidant Effects: A Basis for Drug Selection?
Halliwell, B. (1991) · Drugs · doi:10.2165/00003495-199142040-00003 · Cited by 353
The cell biology of ischemic renal injury
Weinberg, J. M. (1991) · Kidney International · doi:10.1038/ki.1991.58 · Cited by 336
Adenosine receptors: new opportunities for future drugs
Poulsen, S.-A., & Quinn, R. J. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00038-8 · Cited by 280
Sterile inflammation and pregnancy complications: a review
Nadeau-Vallée, M., Obari, D., Palacios, J., Brien, M.-È., Duval, C., Chemtob, S., & Girard, S. (2016) · Reproduction · doi:10.1530/rep-16-0453 · Cited by 275
The role of inflammation in vascular diseases
Sullivan, G. W., Sarembock, I. J., & Linden, J. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.5.591 · Cited by 271
Molecular therapeutics. Methotrexate and its mechanism of action
Cronstein, B. N. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391203 · Cited by 265
Self-citationGrainger, J. R., Wohlfert, E. A., Fuss, I. J., Bouladoux, N., Askenase, M. H., Legrand, F., Koo, L. Y., Brenchley, J. M., Fraser, I. D. C., & Belkaid, Y. (2013) · Nature Medicine · doi:10.1038/nm.3189 · Cited by 264
Regulation of Neutrophil Function by Adenosine
Barletta, K. E., Ley, K., & Mehrad, B. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226845 · Cited by 260
Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
Cronstein, B. N., & Sitkovsky, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.178 · Cited by 258
Self-citationStaphylococcus aureus synthesizes adenosine to escape host immune responses
Thammavongsa, V., Kern, J. W., Missiakas, D. M., & Schneewind, O. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090097 · Cited by 252
Metadata
- Authors
- Cronstein, B. N., Daguma, L., Nichols, D., Hutchison, A. J., & Williams, M.
- Venue
- Journal of Clinical Investigation
- Published
- 1990-04-01
- Volume
- 85
- Issue
- 4
- Pages
- 1150-1157
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2087167599
- Cited by
- 376
- References
- 30
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.